

# ASX ANNOUNCEMENT

25 May 2022

## ANNUAL GENERAL MEETING CHAIRMAN'S ADDRESS AND CHIEF EXECUTIVE OFFICER PRESENTATION

**SYDNEY**, 25 May 2022: Anteris Technologies Ltd (ASX: AVR) is pleased to provide the attached Chairman's Address and Chief Executive Officer Presentation to the Annual General Meeting being held today.

**ENDS**

### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

### Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

### For more information:

Hannah Howlett

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 4 5064 8064

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>

### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



## Address by the Chairman Mr John Seaberg

Thank you from me personally and on behalf of the rest of the Board for allowing us to serve as Directors of your company. The company today looks much different than it did years ago when Wayne and I joined the Board. In that regard, a business mentor of mine, many years ago shared the phrase with me that you should narrow your focus to broaden your appeal. Well, several years ago, we were spread too thin across several businesses and not doing justice to any of them. Also, the markets we were serving were low value targets compared to where we serve today. Thanks to Wayne's transformational leadership we are now laser focused on structural heart, the highest value target in cardiology, and we are blessed with our Platform Technology, our Adapt anti-calcification process, upon which we have been able to develop our leading edge DurAVR TAVR valve and potentially in the future, numerous other structural heart products.

As we've narrowed our focus, we have indeed broadened our appeal. The Key Opinion leaders in our Structural Heart space see much to like about our product and the timing of our product. Remember, these Doctors go to medical meetings all across the globe. It truly is an international community. As we are recognized with various innovation awards at conventions, TAVR professionals all across the world pay attention. The word travels quickly, especially when it references the next big advance in TAVR. Because of our design attributes and the strong success of our first 5 patients in Tblisi Georgia, Wayne has been able to attract and retain a world class Advisory Board. We have been able to welcome TAVR expert, Dr. Chris Meduri to the company as our Chief Medical Officer. We also recently welcomed Dr. Karl Poon from Prince Charles Hospital in Brisbane Australia. Dr Poon has one of the largest TAVI experiences in all of Australia. None of these experts have connected with our company because they are bored with nothing else to do. In fact, they recognize the potential of our company and want to leave their fingerprints on the ultimate design and development of overall clinical strategy. Over the years I've heard more than one Advisory Board doctor express the fact that he can use his expertise in his daily practice on his own patients to save maybe 100's of lives per year but if he can advise industry on how to best develop a technology he can potentially help save thousands of lives per year.

Some of you know that I consult with a Mpls brokerage firm that conducts capital raises for what we deem to be high potential private companies, primarily in the healthcare space. Needless to say we always have to ask ourselves if this is a good time to invest in a specific company, simply put, what is the risk/reward ratio looking like. We look at the management team, the market size, is there an unmet clinical need solved by their product and what is the exit potential for the investors whether via IPO or acquisition. When I apply that thinking to Anteris I see a high quality management team, a product that has successfully gone from bench testing to animals to humans, has a highly differentiated technology in a vibrant and growing market and adequate cash reserves to achieve future milestones. No equity investment is risk free and I'm very biased but from where I sit, we are very investable for the growth minded investor.

Thanks again for your interest and support and we look forward to reporting on our future progress.



# ANTERIS 2021 AGM

## CEO PRESENTATION

May 25<sup>th</sup> 2022



[www.anteristech.com](http://www.anteristech.com) | Follow us @anteristech   

Copyright Anteris Technologies Ltd 2021



# Disclaimer



This presentation contains general information which is current as at 25 May 2022. It is information given in summary form and does not purport to be complete. Information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the financial situation, investment objectives or needs of any particular investor. Before making any investment or other decision, investors should consider these factors, and consult with their own legal, tax, business and/or financial advisors. This presentation should be read in conjunction with all other information concerning Anteris Technologies Ltd filed with the Australian Securities Exchange (ASX). The information in this presentation is for general information only. Anteris advises that this presentation and any related materials and cross-referenced information, may contain forward looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties outside of Anteris' control. No representation is made as to the accuracy or reliability of forward looking statements or the assumptions on which they are based. Actual future events may vary from these forward looking statements and you are cautioned not to place reliance on any forward looking statement. Anteris undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this presentation (subject to ASX disclosure requirements).

ersonal use only







ersonal use only

▲  
2016

▲  
2017

▲  
2018

▲  
2019

▲  
2020

▲  
2021

# Agenda

- Financials
- Competitive advantage
- First in Human study
- Market opportunity
- Partnerships
- Future revenues
- Questions





2021 A year of headlines





### Prince devoted to his queen, dead at 99



Prince Philip, with the Queen in a 2017 portrait, stood back from public duties for years ago, electing to spend his retirement at Sandringham






ersonal use only

# COVID-19 VACCINE





Anteris made a few of its own headlines



**ANTERIS™**

**Selected to showcase the  
DurAVR™ THV System at  
TVT 2021 'Innovation Session'**

**DurAVR™**  
Transcatheter Heart Valve  
*(an ADAPT® Product)*

**Lasts Longer,  
Works Better**






# Major milestones were achieved in 2021



ersonal use only



**Five TAVR Patients  
Successfully  
Implanted With  
DurAVR™ Valve**



DurAVR™ THV Featured at  
PCR London Valley

# DurAVR™ studies progressed rapidly in 2021 from animals to humans


Animal lab




Dr Hamid performing echo



Dr Meduri implanting DurAVR™



DurAVR™ being deployed



ersonal use only

# Financial report

## Balance sheet

<b>Assets</b>	<b>1,734,826</b>
Current assets	88,905
Non-current assets	1,645,921
<b>Liabilities</b>	<b>166,630</b>
Current liabilities	110,327
Non-current liabilities	56,303
<b>Equity</b>	<b>74,393</b>
Paid-in capital	72,921
Retained earnings	1,472



## Equity statement

<b>Current year</b>	<b>1,774,576</b>
Comprehensive income	15,897
Issue of share capital	88,905
Dividends	23,853
<b>Previous year</b>	<b>166,630</b>
Comprehensive income	110,327
Issue of share capital	56,303
Dividends	67,676



## Income statement

<b>Revenues</b>	<b>12,978,516</b>
Net sales	12,873,892
Investment	104,624
<b>Expenses</b>	<b>6,372,535</b>
Research and Development	1,385,395
Depreciation	4,439,118
Amortization	548,022
<b>Net income</b>	<b>6,505,981</b>

## Cash flow statement

<b>Operations</b>	<b>12,978,516</b>
Earnings	12,873,892
Depreciation	104,624
<b>Investing</b>	<b>6,372,535</b>
Real estate	1,385,395
Equipment	4,439,118
<b>Financing</b>	<b>6,505,981</b>
Debt	6,505,981

# 2021 Financials





# Financial highlights 2021

SHARE PRICE  
INCREASED  
**246%**  
TO \$12.96/SHARE

CASH  
**\$21.3M**  
COMPARED TO  
\$4.4M IN 2020

SALES REVENUE  
+ OTHER INCOME  
**\$9.3M**

**50.9**  
TOTAL FULL TIME  
Equivalent Staff  
supporting Anteris'  
business strategy

CAPITAL RAISED  
IN 2021  
**\$41.8M**

PROJECTS SEGMENT  
- R&D EXPENDITURE  
**\$19.5M**

# Anteris market cap increased by 515% in 2021




Key financial metrics	FY2020 Actual \$m	FY2021 Actual \$m
Sales revenue	7.1	7.8
EBITDA	(13.7)	(20.1)
Net loss after tax	(15.3)	(22.9)
Market capitalisation	23.4	143.8
Cash position	4.4	21.3

- **10% increase in ADAPT® sales**
- Overall increase in expenses primarily reflects **increased research and development expenditure relating to the Group's Transcatheter Aortic Valve Replacement (TAVR) program**
- **515% increase in market capitalisation**
- **Significant cash increase through financing activities including proceeds of \$36.8m** from multiple share placements and option conversions; plus \$5m in convertible notes issued to Mercer

# Focused investment in R&D has accelerated progress

## Research & Development \$19.5M


- DurAVR™ valve development program
- Tblisi first-in-human trials
- Design of the TAVR delivery system
- Regulatory and Medical
- Includes allocated indirect costs



## Corporate & Operational \$3.4M

- Capital raising costs
- Company compliance costs
- Insurance
- Financing costs
- Office administration
- IT support
- Net of R&D tax refund


# Operational costs remain stable 20/21



- Corporate + operational costs stable from 2020 to 2021
- R&D costs increased as we entered human studies



# Increasing CardioCel™ production with decreasing costs



2020:

- 77% increase in units
- 23% increase in costs


2021:

- 32% increase in units
- 2% decline in costs


# Highly productive workforce

ersonal use only

## TOTAL EMPLOYEE NUMBERS




## DIVERSITY




# Increased cash balance from equity and non dilutive sources

Personal use only



# Increasing share price and company valuation




ersorally use only

# AVR has returned 141% since the CardioCel™ divestiture

- The S&P/ASX Emerging Companies Index (**XEC**) is a benchmark consisting of 200 Australian microcap companies ranked anywhere between 350 to 600 by market capitalisation
- The below graph compares the performance of the AVR share price vs XEC index over a rolling 12 months

	AVR return	XEC return
Rolling 12 months	84%	17%
Post CardioCel™ divestiture	141%	56%

## Rolling 12 months (incl daily trade volumes)



# AVR has out performed all major health care indices

**Rolling 12 months**

May 2022

160%  
140%  
120%  
100%  
80%  
60%  
40%  
20%  
0%  
-20%  
-40%

- AVR
- S&P/ASX Emerging Companies
- Stoxx Europe 600 Health Care
- S&P Composite 1500 Health Care
- Dow Jones US Medical Equipment Index
- NASDAQ Health Care Index


ersonal use only

# AVR outperformed major competitors



Share price movement (8 April – 9 May 2022)


ersonal use only






# Top 40 investors hold 61% of the Company


## SHAREHOLDER MIX



## OWNERSHIP COUNTRY



## INVESTOR TYPE HISTORY



ersonal use only





Financials only tell part of the story

ersonal use only



Personal use only



How do we compare ?



What is our competitive advantage ?



*ADAPT<sup>®</sup> + DurAVR<sup>™</sup> + ComASUR<sup>™</sup>*



For lifetime management of Aortic  
Stenosis patients

[www.anteristech.com](http://www.anteristech.com) | Follow us @anteristech   

Copyright Anteris Technologies Ltd 2021






ersonal use only



FORMER MANA

# ADAPT<sup>®</sup> the best anti calcification treatment in the world


## Non-reactive fluorescent stain



ADAPT<sup>®</sup>-  
treated  
bioscaffold

All cells and cell remnants have been removed.

## Positive fluorescent stain




0.6%  
GA-treated

Residual cell remnants after processing with 0.6% GA.  
GA=glutaraldehyde.

21ST-CENTURY  
ADAPT TECHNOLOGY<sup>®</sup>  
DEMONSTRATES

**ZERO**  
Residual DNA



DNA content was measured using the Nanodrop method.

An independent analysis of DNA quantification was done by ARFG, Ltg, who is accredited in the field of Biological Testing (Scope: DNA Analysis according to the ISO 17025:2005 standard by the National Association of Biological Testing Authorities (NATA). Multiple samples were tested; ALL demonstrated zero DNA content.<sup>2</sup>

**Completely** removes the potential for calcium-binding sites and antigenic stimulus.

1. Data on file, Admedus  
 2. Data on File, Admedus; AGRF DNA Extraction Reports (CAGRF16022 and CAGRF 15684), 2017  
 3. Neethling et al. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT<sup>®</sup>. The Journal of Heart Valve Disease. 2008; 17:456-463; discussion 464

Personal use only







**WHY IT  
MATTERS?**




# Aortic stenosis is a disease of calcification

Calcium deposits cause a narrowing of the valve opening and an increase in pressure



# DurAVR™ – the first and only 3D single piece TAVR valve in the world

- Designed to be anatomically correct
- Restores pre disease haemodynamics
- Has greater structural integrity
- Opens wider (80%)



Lasts Longer

Works Better



A red rectangular sign with a white border is mounted on a brick wall. The sign is held in place by eight silver-colored screws, two at each corner. The text on the sign is in a white, bold, serif font, arranged in two lines: "WHY IT" on the top line and "MATTERS?" on the bottom line. The background of the sign is a solid, vibrant red. The brick wall behind it is made of reddish-brown bricks with visible mortar lines.

**WHY IT  
MATTERS?**



## Younger patients need longer lasting next generation valve technology

Younger patients now eligible



**Guidelines**  
TAVR as class(I) for ages 65-80



**Indications:**

- Moderate
- Asymptomatic



What Does this Mean?

Valves now need to last 10-15 years

Patient Age



Key Considerations

Life Expectancy  
Exercise Capacity

- Mean age has moved from **85** to **73** in less than a year
- 2019 was 1<sup>st</sup> year where TAVR procedures outpaced SAVR

# ComASUR™ Delivery System



ersonal use only








**WHY IT  
MATTERS?**





# Severe aortic stenosis requires the aortic valve to be replaced

## SAVR (Surgical Aortic Valve Replacement)



## TAVR (Transcatheter Aortic Valve Replacement)



ersonal use only

# Today's TAVR's need to address 4 key medical needs



## Current products fall short in two critical areas

Predictable Procedure

Optimal Hemodynamic Performance

Low Incidence of Complications

Durability

Predictable Procedure

Performance Hemodynamic

Complications Low Incidence of

Durability

Competitor products leave the patient in "mild" stenosis immediately post implantation

Competitor products can start to deteriorate within 12 months and may need replacement within 5 years



# DurAVR™ THV satisfies all 4 key areas



ComASUR™ delivery system is more predictable with commissural alignment

Better haemodynamics at rest and during increased cardiac output (exercise)


DurAVR's™ 3D uni-body design has greater structural integrity + ADAPT® anti calcification treatment

Predictable Procedure

Optimal Haemodynamic Performance

Low Incidence of Complications

Durability



**DurAVR™**  
Transcatheter Heart Valve

(an ADAPT® Product)







**WHY IT  
MATTERS?**

# Current TAVR products were not designed for younger patients



1<sup>st</sup> Generation TAVR's designed to solve a different problem to today's patients needs

*Patient needs a safe alternative to open heart surgery"*

*"Patient needs a valve that restores an active lifestyle for the rest of their life"*

1<sup>st</sup> and 2nd  
GENERATION  
TAVR

**>85yrs**



2010 – 2019 Average patient age was 85



**DurAVR™**

3<sup>rd</sup> Generation

**>65yrs**

From 2019 the average patient age is 73 and declining

DurAVR™ was designed for younger active patients



ersonal use only





"Skate to where the puck is going,  
not where it has been."

— Wayne Gretzky



# FIRST IN HUMAN

BEFORE THE BREAKTHROUGH  
COMES THE TRIAL

ersonal use only










# DurAVR™ First-in-Human Study: *Individual Patient Case Example*



## FIH 30-day DurAVR™ haemodynamics:

- Area Derived Annulus Size 21.3mm
- EOA = 2.02 cm<sup>2</sup>
- DVI = 0.66
- Intra-op Coaptation length = 10.3 mm

---

### EOA compared to annulus size matched benchmark\*:

- Sapien 3 = 1.41 cm<sup>2</sup> +/- 0.27
- Evolut R = 1.66 cm<sup>2</sup> +/- 0.42



# ComASUR™ A unique Physician designed delivery system



## Easy and Predictable Commissural Alignment




- Intuitive handle design
- Precise balloon expandable deployment
- Unique ability to rotate valve at annular level for consistent, predictable commissural alignment





ersonal use only


# Near perfect laminar flow, unique in the valve space



DurAVR™ has perfect laminar flow!




Poor laminar flow observed in other products leads to early valve deterioration.




We were successful in the most challenging patient group


Severe Annular Calcium



Extreme Leaflet Calcium



Type 1 Bicuspid



ersonal use only




# DurAVR™ First-in-Human Study


## Challenging Anatomical Conditions Treated




Severe Annular Calcium



Extreme Leaflet Calcium



Type 1 Bicuspid



Baseline CTs



ersonal use only

# DurAVR™ - Commissural alignment

## Excellent Commissural Alignment & Leaflet Function







30-day CT

# DurAVR™ Different to the competitors by design

## Unique Design of a Single Piece of Tissue 3D Molded to Mimic the Native Aortic Valve Anatomy

- Designed in diastole (closed position)
- Opens wider with less pressure
- Remains open longer with the purpose of improving haemodynamics




\* Data on file, Anteris


\*\* Lim KH et al., Flat or Curved Pericardial Aortic Valve Cusps: A Finite Element Study. J Heart Valve Dis. 2004;13:792-797.



# DurAVR™ THV: Outperforms the competitors in every regard




## DurAVR™ Computational Fluid Model\*



- 85% greater coaptation area\*\*
- 35% lower leaflet strain\*\*
- Optimal laminar flow\*

## Coaptation Modeling\*



Personal use only

\*Data on file, Anteris  
 \*\*Lim KH et al., Flat or Curved Pericardial Aortic Valve Cusps: A Finite Element Study. J Heart Valve Dis. 2004;13:792-797.

# DurAVR™ 3D Single Piece THV with ADAPT®



## Exercise Capacity

Valve that restores near-normal haemodynamics

## Durability


Valve that lasts the lifetime of the patient

## Future Management

Valve that allows for future intervention

## PROVEN TISSUE DURABILITY

Superior anti-calcification tissue process (ADAPT®)\*



## NEAR-NORMAL HEMODYNAMICS

Unique 3D single-piece valve design with large EOA, 85% greater coaptation and 35% less stress\*\*

## IMPROVED CORONARY ACCESS

Large, open cell geometry

## ComASUR™ TF Delivery System

Ability to uniquely rotate valve at the annular level for predictable commissural alignment



## PARAVALULAR LEAK SOLUTION

Proven benefits of PET outer skirt

\* Data on file, Anteris

\*\* Lim KH et al., *Flat or Curved Pericardial Aortic Valve Cusps: A Finite Element Study*. J Heart Valve Dis. 2004;13:792-797.

If I had asked people  
**what they wanted,**  
they would have said  
**a faster horse**


- Henry Ford





ersonal use only

In the end its all about patients





ersonal use only

Next cohort  
of patients  
being  
implanted  
now !



ersonal use only



TBILISI, GEORGIA, 25/5/22. FIH.



ersonal use only

Market opportunity



# AVR Market Growth


- USD 14 billion by 2028
- US CAGR 12%
- US 42% of the market in 2021
- 75% of AVR will be TAVR by 2028



# The Global TAVR market will continue to show strong growth into the future

## TAVR PROCEDURES 2020 -2028


■ US ■ OUS



## TAVR REVENUE 2020 -2028

■ US ■ OUS

USD Billions




Personal use only




# TAVR/SAVR Regional Market share

Personal use only


## 2021 TAVR/Surgical Aortic Stenosis Procedures




## TAVR Procedures by Regions



## EU TAVR Market Share 2021



## US TAVR Market Share 2021




**Edwards and Medtronic combined have ~88% of the Global TAVR Market**


# 2021 TAVR Market Share US EU

ersonal use only

### US Market TAVR Share 2021




### EU TAVR Market Share 2021




# 2021 to 2028 TAVR vs Surgical Procedures: US

ersonal use only

### 2021 US TAVR/Surgical Aortic Stenosis Procedures



### 2028 US TAVR/Surgical Aortic Stenosis Procedures







# 2021 Global Procedures vs Revenue

ersonal use only

### Global 2021 TAVR Surgical Aortic Stenosis Procedures



### Global 2021 TAVR Surgical Revenue US\$



## Key Partnerships



---

- Anteris has entered key Academic partnerships with the following:
- Yale University
- Columbia University
- UWA



# We are also engaged in partnerships for next generation valve materials

- Currently Anteris is actively researching two distinct technologies that will allow us to replicate the design benefits of the DurAVR™ valve in new materials. The company has entered multiple partnerships researching alternate valve materials to ensure there are follow on products to ADAPT® /DurAVR™ into the future
- These include a collaboration researching MEW technology (**Melt electrowriting**) (MEW) is an advanced additive manufacturing technique capable of depositing predefined micrometric fibers.
- The second one is confidential but is on the bench being tested at the moment



ersonal use only



Personal use only



| Future Revenues

# First TAVR revenues in 2023



- Anteris TAVR studies will potentially qualify as a Category B study
- Anteris will commence supplying product during its FDA studies at approx USD25k per unit
- First TAVR revenues will commence in 2023

Personal use only

- Key presentations







# Questions


- Market valuation
- When can we start selling DurAVR™
- Nasdaq listing progress/structure
- Development milestones
- FIH TAVR
- SAVR study
- EFS FDA study
- R&D Further developments

ersonal use only



THANK  
YOU





# Board of Directors




John Seaberg  
Director and Chair



Wayne Paterson  
Director and  
Chief Executive Officer



Stephen Denaro  
Director and  
Company Secretary



Wenyi Gu  
Director

ersonal use only



# Executive Team



David St. Denis  
Chief Operating Officer






Matthew McDonnell  
Chief Financial Officer



Christopher Meduri  
Chief Medical Officer

ersonal use only

# Anteris is supported by highly qualified advisors



**Bernard Prendergast, MD**  
Guy's & St. Thomas'  
London, UK (A/S)

**Michael Reardon, MD**  
Houston Methodist  
Houston, TX

**Samir Kapadia, MD**  
Cleveland Clinic  
Cleveland, OH (A/S)

**Gorav Ailawadi, MD**  
Univ of Virginia Charlottesville, VA  
(A/S)

**Thomas Modine, MD**  
CHU de Bordeaux  
Bordeaux, FR

**Nicolas Van Mieghem, MD**  
Erasmus Univ Med Center  
Rotterdam, NL

**Karl Poon, MBBS**  
St Andrews War Memorial  
The Prince Charles Hospital  
Brisbane

**Jayme Bennetts, BMBS**  
Ashford Community Hospital  
Calvary Adelaide Hospital  
Flinders Medical Center  
Bedford Park



**Vinayak Bapat, MD**  
Abbott Northwestern  
Minneapolis, MN (A/S)

**Paul Sorajja, MD**  
Abbott Northwestern  
Minneapolis, MN (A/S)

**Susheel Kodali, MD**  
Columbia Medical Center  
New York, NY (A/S)

**Allen Zajarias, MD**  
Washington Univ  
St. Louis, MO (A/S)

**Nadira Hamid, MD**  
Columbia Medical Center  
New York, NY

**Magnus Settergren, MD**  
Karolinska University Hospital  
Stockholm, SE

**Didier Tchetché, MD**  
Clinique Pasteur  
Toulouse, FR

**Ajay Sinhal, MBBS, MD**  
Ashford Community Hospital  
Calvary Adelaide Hospital  
Flinders Medical Center  
Adelaide

**Dion Stub, MBBS, PhD**  
Cabrin Private Hospital  
Western Health  
The Alfred Hospital  
South Australia



**Rebecca Hahn, MD**  
Columbia Medical Center  
New York, NY

**Joao Cavalcante, MD**  
Abbott Northwestern  
Minneapolis, MN

**Janar Sathananthan, MD**  
St. Paul's & VGH  
Vancouver, BC

**Alexandra Lansky, MD**  
Yale  
New Haven, CT

**Azeem Latib, MD**  
Montefiore Med Center  
New York, NY





# Anteris has a highly talented and engaged team



ersonal use only



# A great team in the right locations

## Exceptional individuals doing exceptional things

APAC



Biologics Manufacturing / R&D  
(Malaga, Australia)

Finance & IT Team  
(Brisbane, Australia)



USA



Innovation Centre & Corporate HQ  
(Minneapolis, USA)



Europe



Strategic Hub in Europe  
(Geneva, Switzerland)



ersonal use only

Lasts Longer,  
Works Better

**ANTERIS**  
TECHNOLOGIES  
A Structural Heart Company

**DurAVR™**  
TRANSCATHETER HEART VALVE SYSTEM



A Valve Designed  
for Life.